Significant Ownership of Vestal Point Capital, LP

Signature - Title
/s/ Ryan Wilder - By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Vestal Point Capital, LP.

Notify me when Vestal Point Capital, LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Vestal Point Capital, LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TENX TENAX THERAPEUTICS, INC. Common Stock, par value $0.0001 per share 9.9% $18,525,720 2,470,096 Vestal Point Capital, LP 30 Sep 2024
IBIO iBio, Inc. Common Stock, par value $0.001 per share 9.9% $3,518,752 4,275,000 Vestal Point Capital, LP 30 Sep 2025
ANRO Alto Neuroscience, Inc. Common Stock, par value $0.0001 per share 8% $41,002,500 2,485,000 Vestal Point Capital, LP 31 Dec 2025
SLDB Solid Biosciences Inc. Common Stock, par value $0.001 per share 7.5% $32,796,600 +$22,906,533 5,815,000 +232% Vestal Point Capital, LP 31 Dec 2025
LXEO Lexeo Therapeutics, Inc. Common Stock, par value $0.0001 per share 7.5% $27,338,885 +$5,903,896 4,117,302 +28% Vestal Point Capital, LP 30 Sep 2025
ELVN Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share 6.5% $98,622,500 3,830,000 Vestal Point Capital, LP 31 Dec 2025
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 6.5% $62,669,750 -$24,980,250 3,575,000 -28% Vestal Point Capital, LP 31 Dec 2025
CBIO CRESCENT BIOPHARMA, INC. Ordinary Shares, par value $0.001 per share 5.4% $16,575,000 1,500,000 Vestal Point Capital, LP 31 Dec 2025
IMTX Immatics N.V. Ordinary Shares, nominal value 0.01 euro per share 5.3% $30,559,250 6,275,000 Vestal Point Capital, LP 31 Dec 2024
ACLX Arcellx, Inc. Common Stock, par value $0.001 per share 5.1% $193,839,750 2,925,000 Vestal Point Capital, LP 31 Dec 2025
DAWN Day One Biopharmaceuticals, Inc. Common Stock, par value $0.0001 per share 5.1% $55,068,000 5,200,000 Vestal Point Capital, LP 31 Dec 2025
TSHA Taysha Gene Therapies, Inc. Common Stock, par value $0.00001 per share 5% $70,675,000 13,750,000 Vestal Point Capital, LP 31 Dec 2025
TYRA Tyra Biosciences, Inc. Common Stock, par value $0.0001 per share 4.5% $33,925,750 -$6,363,058 2,425,000 -16% Vestal Point Capital, LP 30 Sep 2025
NYXH Nyxoah SA Ordinary Shares, no nominal value per share 3.7% $10,599,135 -$6,932,157 1,402,002 -40% Vestal Point Capital, LP 30 Jun 2025
DNTH Dianthus Therapeutics, Inc. /DE/ Common Stock, par value $0.001 per share 3% $46,433,000 -$79,487,000 1,180,000 -63% Vestal Point Capital, LP 30 Sep 2025
SVRA Savara Inc Common Stock, par value $0.001 per share 2.3% $14,333,550 -$24,133,200 4,015,000 -63% Vestal Point Capital, LP 30 Sep 2025
KALV KalVista Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 1.5% $9,135,000 750,000 Vestal Point Capital, LP 30 Sep 2025
BDTX Black Diamond Therapeutics, Inc. Common Stock, par value $0.0001 per share 1.5% $2,166,300 870,000 Vestal Point Capital, LP 31 Dec 2025
QURE uniQure N.V. Ordinary Shares, par value 0.05 euro per share 0.4% $13,133,250 -$202,835,750 225,000 -94% Vestal Point Capital, LP 30 Sep 2025
APLT Applied Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$1,150,000 0 -100% Vestal Point Capital, LP 31 Dec 2025
ATXS Astria Therapeutics, Inc. Common Stock, par value $0.001 per share 0% $0 -$63,040,320 0 -100% Vestal Point Capital, LP 31 Dec 2025

Schedules 13D/G Reported by Vestal Point Capital, LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.